Risk factors for oral mucositis during chemotherapy treatmentfor solid tumors: a retrospective STROBE-guided study
Martins, Joyce Ohana de Lima; Borges, Marcela Maria Fontes; Malta, Cássia Emanuella Nóbrega; Carlos, Anna Clara Aragão Matos; Crispim, André Alves; Moura, José Fernando Bastos de; Fernandes-Lima, Isabelle Joyce Silva; Silva, Paulo Goberlânio de Barros.
Med. oral patol. oral cir. bucal (Internet)
; 27(4): 1-11, July 2022. tab
Artículo
en Inglés
| IBECS (España) | ID: ibc-209795
Background:
This study retrospectively analyzed the risk factors for transchemotherapy oral mucositis (OM).Material andMethods:
Before each chemotherapy cycle, patients were routinely evaluated for the presence/severity of OM based on the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 scale for adverse effectsand graded as follows However, specific conditions such as mucositis are graded on a five-point scale 0, absenceof mucositis, grade 1 (Asymptomatic or mild), 2 (Presence of pain and moderate ulceration, without interferencewith food intake), 3 (severe pain with interference with food intake) or 4 (Life-threatening with the need for urgentintervention). Information from 2 years of evaluations was collected and patient medical records were reviewed toobtain data on chemotherapy cycle, sex, age, body mass index, body surface area, primary tumor, chemotherapyprotocol, and history of head and neck radiotherapy. The X² test and multinomial logistic regression were used forstatistical analysis (SPSS 20.0, p<0.05).Results:
Among 19,000 total evaluations of 3,529 patients during 5.32±4.7 chemotherapy cycles (CT) the prevalence of OM was 6.3% (n=1,195). Chemotherapy duration (p<0.001), female sex (p=0.001), adjuvant intention(p=0.008) and the use of carboplatin (p=0.001), cisplatin (p=0.029), docetaxel (p<0.001) and bevacizumab(p=0.026) independently increased the risk of mucositis. In head and neck tumors, 2018 year (p=0.017), chemotherapy duration (p=0.018), BMI>30 (p=0.008), radiotherapy (p=0.037) and use of carboplatin (p=0.046) andcyclophosphamide (p=0.010) increased this prevalence.Conclusions:
Cycles of chemotherapy, sex, cytotoxicity drugs, bevacizumab and head and neck radiotherapy increase the risk of OM in solid tumors. (AU)
Biblioteca responsable:
ES1.1
Ubicación: ES15.1 - BNCS
Texto completo
Documentos relacionados